Posted on:Weil in the News
Weil is advising Antin Infrastructure Partners (“Antin”) in its acquisition of FirstLight, a leading fiber-optic bandwidth infrastructure services provider operating in the Northeast U.S. The financial terms of the agreement were not disclosed and the transaction is expected to close during the second half of 2018, subject to customary regulatory approvals and customary closing conditions.
James MacArthur, who also advised Antin on their acquisition of the Central Area Transmission System (CATS) in the Central North Sea commented: “We have built an excellent relationship with Antin in Europe, having recently acted for them on their purchase of ETS in the U.K. and the sale of FPS Towers in France, amongst others. It was, therefore, a privilege to work alongside Antin on their first deal in the U.S., and we look forward to helping them grow their presence in the U.S. in the near future. This deal demonstrates perfectly the global platform offered to our clients by our Real Assets Practice.”
The Weil team advising Antin is led by Private Equity partners Brian Gingold and Shayla Harlev and includes Real Assets partner James MacArthur; Corporate associates Jenna McBain, Benjamin Adelson, Sean Fitzpatrick, Constantinos Pappas and Emmanuel Charles (Not Yet Admitted in New York); Banking & Finance partners Douglas Urquhart and Paul Hibbert; Technology & IP Transactions partner Michael Epstein; Tax partners Kimberly Blanchard and Mark Schwed; Executive Compensation & Benefits partner Michael Nissan; International Arbitration & Trade partner Ted Posner; Environmental counsel John O’Loughlin; Antitrust counsel Vadim Brusser; Banking & Finance associates Erin Cartledge and Nick Nikic; Technology & IP Transactions associates Christine Paik and Phillip Grudzina (Not Yet Admitted in New York); Tax associates Adam Arikat and Liam Murphy; Executive Compensation & Benefits associates Jennifer Haydel Britz and John Kleinjan; Insurance associate Gabriel Gershowitz; Antitrust associate Jonathan Cheng; and Regulatory associate Timothy Welch.